IDEAS home Printed from https://ideas.repec.org/f/pha1057.html
   My authors  Follow this author

Alan Haycox

Personal Details

First Name:Alan
Middle Name:
Last Name:Haycox
Suffix:
RePEc Short-ID:pha1057
https://www.liv.ac.uk/management/staff/alan-haycox/

Affiliation

(50%) Regional and International Economic Development Group
Management School
University of Liverpool

Liverpool, United Kingdom
http://tulip.liv.ac.uk/portal/pls/portal/tulwwwmerge.mergepage?p_template=rae_rg_regi1&p_tulipproc=raerg&p_params=0.000000p_func0SIBL14b61aa0_param07874014b61aa0_template0rae_rg_regi1
RePEc:edi:delivuk (more details at EDIRC)

(50%) Management School
University of Liverpool

Liverpool, United Kingdom
http://www.liverpool.ac.uk/management/
RePEc:edi:mslivuk (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Ken Wright & Alan Haycox, 1985. "Costs of alternative forms of NHS care for mentally handicapped persons," Working Papers 007chedp, Centre for Health Economics, University of York.
  2. Ken Wright & Alan Haycox, 1984. "Public sector costs of caring for mentally handicapped persons in a large hospital," Working Papers 001chedp, Centre for Health Economics, University of York.

Articles

  1. Cochrane, M. & Watson, P.M. & Timpson, H. & Haycox, A. & Collins, B. & Jones, L. & Martin, A. & Graves, L.E.F., 2019. "Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions," Social Science & Medicine, Elsevier, vol. 232(C), pages 156-167.
  2. Alan Haycox, 2018. "Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries?," PharmacoEconomics, Springer, vol. 36(7), pages 731-732, July.
  3. Arianit Jakupi & Brian Godman & Antony Martin & Alan Haycox & Indrit Baholli, 2018. "Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications," PharmacoEconomics - Open, Springer, vol. 2(4), pages 423-432, December.
  4. Alessandra Ferrario & Diāna Arāja & Tomasz Bochenek & Tarik Čatić & Dávid Dankó & Maria Dimitrova & Jurij Fürst & Ieva Greičiūtė-Kuprijanov & Iris Hoxha & Arianit Jakupi & Erki Laidmäe & Olga Löblová , 2017. "The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications," PharmacoEconomics, Springer, vol. 35(12), pages 1271-1285, December.
  5. Alan Haycox, 2016. "Why Cancer?," PharmacoEconomics, Springer, vol. 34(7), pages 625-627, July.
  6. Alan Haycox & Munir Pirmohamed & Claire McLeod & Rachel Houten & Sarah Richards, 2014. "Through a Glass Darkly: Economics and Personalised Medicine," PharmacoEconomics, Springer, vol. 32(11), pages 1055-1061, November.
  7. Alan Haycox, 2013. "How Much Should the NHS Pay for a QALY?," PharmacoEconomics, Springer, vol. 31(5), pages 357-359, May.
  8. Magda Wladysiuk & Aleksander Araszkiewicz & Brian Godman & Katarzyna Szabert & Corrado Barbui & Alan Haycox, 2011. "Influence of patient co-payments on atypical antipsychotic choice in Poland," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 101-110, March.
  9. Alan Haycox, 2007. "When NICE Says No!," PharmacoEconomics, Springer, vol. 25(12), pages 995-996, December.
  10. Alan Haycox, 2006. "Book Review: Valuing Health in Practice: Priorities, QALYs and Choice," Journal of Interdisciplinary Economics, , vol. 17(3), pages 345-347, April.
  11. Dyfrig A. Hughes & Adrian Bagust & Alan Haycox & Tom Walley, 2001. "The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: a review of the literature," Health Economics, John Wiley & Sons, Ltd., vol. 10(7), pages 601-615, October.
  12. Johnes, Geraint & Haycox, Alan, 1986. "Cost structures in a large hospital for the mentally handicapped," Social Science & Medicine, Elsevier, vol. 22(6), pages 605-610, January.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Ken Wright & Alan Haycox, 1985. "Costs of alternative forms of NHS care for mentally handicapped persons," Working Papers 007chedp, Centre for Health Economics, University of York.

    Cited by:

    1. Office of Health Economics, 1986. "Mental Handicap: Partnership in the Community?," Series on Health 000353, Office of Health Economics.
    2. Jeremy Hurst, 1998. "The impact of health economics on health policy in England, and the impact of health policy on health economics, 1972–1997," Health Economics, John Wiley & Sons, Ltd., vol. 7(S1), pages 47-61, August.

  2. Ken Wright & Alan Haycox, 1984. "Public sector costs of caring for mentally handicapped persons in a large hospital," Working Papers 001chedp, Centre for Health Economics, University of York.

    Cited by:

    1. Knapp, Martin & Comas-Herrera, Adelina & Astin, Jack & Beecham, Jennifer & Pendaries, Claude, 2005. "Intellectual disability, challenging behaviour and cost in care accommodation: what are the links?," LSE Research Online Documents on Economics 336, London School of Economics and Political Science, LSE Library.

Articles

  1. Cochrane, M. & Watson, P.M. & Timpson, H. & Haycox, A. & Collins, B. & Jones, L. & Martin, A. & Graves, L.E.F., 2019. "Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions," Social Science & Medicine, Elsevier, vol. 232(C), pages 156-167.

    Cited by:

    1. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2022. "Does providing everyone with free-of-charge organised exercise opportunities work in public health?," Health Policy, Elsevier, vol. 126(2), pages 129-142.
    2. Thiboonboon, Kittiphong & Lourenco, Richard De Abreu & Cronin, Paula & Khoo, Terence & Goodall, Stephen, 2024. "Economic Evaluations of Obesity-Targeted Sugar-Sweetened Beverage (SSB) Taxes–A Review to Identify Methodological Issues," Health Policy, Elsevier, vol. 144(C).
    3. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2020. "Modelling the impact of physical activity on public health: A review and critique," Health Policy, Elsevier, vol. 124(10), pages 1155-1164.

  2. Arianit Jakupi & Brian Godman & Antony Martin & Alan Haycox & Indrit Baholli, 2018. "Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications," PharmacoEconomics - Open, Springer, vol. 2(4), pages 423-432, December.

    Cited by:

    1. Wânia Cristina Silva & Brian Godman & Francisco Acúrcio & Mariângela Leal Cherchiglia & Antony Martin & Konrad Maruszczyk & Jans Bastos Izidoro & Marcos André Portella & Agner Pereira Lana & Orozimbo , 2021. "The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil," Applied Health Economics and Health Policy, Springer, vol. 19(4), pages 557-577, July.
    2. Ilir Hoxha & Valid Apuk & Besfort Kryeziu & Premtim Rashiti & Mrika Aliu & Alejandro Gonzalez Aquines & Olga Khan & Ha Thi Hong Nguyen, 2023. "Management of Non-Communicable Diseases in Kosovo: A Scoping Review," IJERPH, MDPI, vol. 20(4), pages 1-16, February.

  3. Alessandra Ferrario & Diāna Arāja & Tomasz Bochenek & Tarik Čatić & Dávid Dankó & Maria Dimitrova & Jurij Fürst & Ieva Greičiūtė-Kuprijanov & Iris Hoxha & Arianit Jakupi & Erki Laidmäe & Olga Löblová , 2017. "The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications," PharmacoEconomics, Springer, vol. 35(12), pages 1271-1285, December.

    Cited by:

    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Kwon, Hye-Young & Bae, Seungjin & Choi, Sang-eun & Park, Sylvia & Lee, Eui-Kyung & Park, Sungmin & Kim, Jinhyun, 2019. "Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea," Health Policy, Elsevier, vol. 123(4), pages 388-392.
    3. Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.
    4. Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016," Health Policy, Elsevier, vol. 123(8), pages 713-720.
    5. Biancalani, Francesco & Gnecco, Giorgio & Riccaboni, Massimo, 2022. "Price-volume agreements: A one principal/two agents model," European Journal of Operational Research, Elsevier, vol. 300(1), pages 296-309.
    6. García-Collado, Carlos Gustavo & Martínez-de-la-Plata, Juan Enrique & Montoro, María del Mar Maldonado & Morales, Alberto Jiménez & Hernández, Miguel Ángel Calleja & Martínez, Fernando Martínez, 2021. "Impact of a risk-sharing agreement in rheumatoid arthritis in Spain," Health Policy, Elsevier, vol. 125(3), pages 335-340.
    7. Nasuh C. Buyukkaramikli & Peter Wigfield & Men Thi Hoang, 2021. "A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 51-73, February.

  4. Alan Haycox, 2013. "How Much Should the NHS Pay for a QALY?," PharmacoEconomics, Springer, vol. 31(5), pages 357-359, May.

    Cited by:

    1. James F. O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    2. Alan Haycox, 2016. "Why Cancer?," PharmacoEconomics, Springer, vol. 34(7), pages 625-627, July.
    3. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.

  5. Magda Wladysiuk & Aleksander Araszkiewicz & Brian Godman & Katarzyna Szabert & Corrado Barbui & Alan Haycox, 2011. "Influence of patient co-payments on atypical antipsychotic choice in Poland," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 101-110, March.

    Cited by:

    1. Sabine Vogler & Guillaume Dedet & Hanne Bak Pedersen, 2019. "Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries," Applied Health Economics and Health Policy, Springer, vol. 17(6), pages 803-816, December.

  6. Dyfrig A. Hughes & Adrian Bagust & Alan Haycox & Tom Walley, 2001. "The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: a review of the literature," Health Economics, John Wiley & Sons, Ltd., vol. 10(7), pages 601-615, October.

    Cited by:

    1. Depalo, D.;, 2019. "Explaining the causal effect of adherence to medication on cholesterol through the marginal patient," Health, Econometrics and Data Group (HEDG) Working Papers 19/13, HEDG, c/o Department of Economics, University of York.
    2. Pierre-Yves Geoffard & Karine Lamiraud, 2007. "Therapeutic non adherence: A rational behavior revealing patient preferences?," Post-Print halshs-00754193, HAL.
    3. Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.
    4. Srivastava, Divya & McGuire, Alistair, 2015. "Patient access to health care and medicines across low-income countries," Social Science & Medicine, Elsevier, vol. 133(C), pages 21-27.
    5. Afschin Gandjour & Karl Wilhelm Lauterbach, 2003. "When Is It Worth Introducing a Quality Improvement Program? A Mathematical Model," Medical Decision Making, , vol. 23(6), pages 518-525, November.
    6. Abualbishr Alshreef & Nicholas Latimer & Paul Tappenden & Ruth Wong & Dyfrig Hughes & James Fotheringham & Simon Dixon, 2019. "Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Method," Medical Decision Making, , vol. 39(8), pages 910-925, November.
    7. François-Emery Cotté & Bruno Fautrel & Gérard De Pouvourville, 2009. "A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis," Medical Decision Making, , vol. 29(1), pages 125-139, January.
    8. Rotar, Alexandru M. & Preda, Alin & Löblová, Olga & Benkovic, Vanesa & Zawodnik, Szymon & Gulacsi, Laszlo & Niewada, Maciej & Boncz, Imre & Petrova, Guenka & Dimitrova, Maria & Klazinga, Niek, 2018. "Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries," Health Policy, Elsevier, vol. 122(3), pages 230-236.
    9. Vincenzo Atella & Federico Belotti & Domenico Depalo, 2017. "Drug therapy adherence and health outcomes in the presence of physician and patient unobserved heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 26(S2), pages 106-126, September.
    10. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
    11. Domenico Depalo & Jay Bhattacharya & Vincenzo Atella & Federico Belotti, 2019. "When Technological Advance Meets Physician Learning in Drug Prescribing," NBER Working Papers 26202, National Bureau of Economic Research, Inc.
    12. Danielle Brunenberg & Gwenn Wetzels & Patricia Nelemans & Carmen Dirksen & Johan Severens & Henri Stoffers & Jan Schouten & Martin Prins & Peter Leeuw & Manuela Joore, 2007. "Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients," PharmacoEconomics, Springer, vol. 25(3), pages 239-251, March.
    13. Robyn Tamblyn & Kristen Reidel & Allen Huang & Laurel Taylor & Nancy Winslade & Gillian Bartlett & Roland Grad & André Jacques & Martin Dawes & Pierre Larochelle & Alain Pinsonneault, 2010. "Increasing the Detection and Response to Adherence Problems with Cardiovascular Medication in Primary Care through Computerized Drug Management Systems: A Randomized Controlled Trial," Medical Decision Making, , vol. 30(2), pages 176-188, March.
    14. Afschin Gandjour & Karl Wilhelm Lauterbach, 2005. "How Much Does It Cost to Change the Behavior of Health Professionals? A Mathematical Model and an Application to Academic Detailing," Medical Decision Making, , vol. 25(3), pages 341-347, May.
    15. Hege Urdahl & Andrea Manca & Mark Sculpher, 2006. "Assessing Generalisability in Model-Based Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 24(12), pages 1181-1197, December.
    16. Hiligsmann, Mickaël & Rabenda, Véronique & Bruyère, Olivier & Reginster, Jean-Yves, 2010. "The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients," Health Policy, Elsevier, vol. 96(2), pages 170-177, July.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Alan Haycox should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.